Chiesi Farmaceutici S.p.a.

Kemin Industries, Inc.

Università Degli Studi Di Parma

Almira Pharma Srl

Mdt Int'l S.a.

Eurhema S.r.l.

Ruggero Bettini

Paolo Colombo

Pier Luigi Catellani

Paolo Ventura

Giovanni Caponetti

Francesca Schiaretti

Francesca Buttini

Andrea Benassi

Enrico Salomi

Patrizia Santi

Lauro Arduini

Ferdinando Giordano

Marta Cito

Viviana Mascilongo

Fabio Borella

Adolfo Gasparetto

Fabio Sonvico

Claudia Camellini

Francesca Bertolini

Antonello Romani

Nicoletta Ronda

Franco Bernini

Annalisa Bianchera

Massimo Coruzzi

Lisa Elviri

Angelo Borghetti

The present invention relates to pharmaceutical composition for the oral delivery of Pentosan Polysulfate sodium (PPS). In particular, the invention discloses compositions of PPS in form of nanoparticles with a suitable polymer aimed to improve the PPS absorption in the small intestine and reduce or eliminate the side effects in the colon.

Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption

Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.

Carrier particles for dry powder formulations for inhalation

Microparticles or granules intended for use in the zootechnical field, constituted by a core which contains a substance having a pharmacological action, a food supplement or a diagnostic medium, intimately mixed or adsorbed with a hydrated silicate of magnesium, aluminum, calcium and sodium (smectite, montmorillonite or bentonite); the core is coated with a double fatty layer constituted by two fats or waxes, of which the one having the highest melting point constitutes the inner layer while the one having the lowest melting point is arranged so as to form the outer layer. The ability to control release effectively and accordingly reduce rumen degradation of active substances which contain a cationic or an anionic chemical function, such as for example choline chloride lysine hydrochloride, calcium chloride, citric acid, ascorbic acid or nicotinic acid is determined by the synergistic action of two phenomena: an interaction between the active substance and the other component of the core, and the barrier effect of the double fat layer. Taken individually, the two phenomena are unable to apply effective control over the release of the active substance.

Compositions of microparticles and granules for oral controlled release of substances for veterinary use

An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in space depends on the way in which the modules have been assembled. The modular structure offers high reproducibility of manufacture and flexibility of release.

Modular systems for the controlled release of a substance with space and time control

A process for the preparation of inclusion complexes of a drug (piroxicam or ibuprofen) and a cyclodextrin, characterised in that: a) the drug and cyclodextrin, in the form of finely divided powders, are mixed in the presence of aqueous or hydroalcoholic solutions, ammonia solutions or acid solutions; b) the resulting mixture is treated in a microwave oven; c) the resulting product is dried under vacuum at room temperature or with heating.

Process for preparation of inclusion compounds between a non-steroidal anti-inflammatory drug and betacyclodextrin by microwave treatment

Carrier particles, for use in the preparation of powdery mixtures for administration by inhalation, and having a median diameter of greater than 90 microns and a surface rugosity expressed as the fractal dimension of less than or equal to 1.1, may be prepared by subjecting particles having a median diameter of greater than 90 microns to repeated stages of wetting with a solvent and drying.

Powder particles with smooth surface for use in inhalation therapy

Carriers for use in the preparation of mixtures for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described.

Growing community of inventors

Parma, Italy

Ruggero Bettini